Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.
Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.
Osage University Partners has celebrated an exit as migraine treatment developer Satsuma Pharmaceuticals listed on the Nasdaq Global Market following an $82.5m offering.
The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.
Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.
Osage University Partners-backed Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.